13F Holdings
中文EN

AKBA Akebia Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1517022 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-12.4%
TTM net income YoY-180.2%
TTM EPS YoY-112.5%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—

Margins

Gross margin78.9%
Operating margin-15.7%
Net margin-22.6%
FCF margin7.0%
EBITDA margin-15.1%

Returns

ROE-143.8%
ROA-12.6%
ROIC (approx.)—
Asset turnover0.56x

Leverage & solvency

Liabilities / assets94.0%
Debt / equity2.47x
Current ratio1.36x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.35x
Accruals ratio-17.1%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$236.20M$160.18M$194.62M$292.48M$211.65M
Cost of revenue$39.46M$63.18M$74.15M$85.57M$150.67M
Gross profit$196.73M$97.00M$120.47M$206.92M$60.98M
R&D expense$62.36M$37.65M$63.08M$129.99M$147.85M
SG&A expense$107.48M$106.55M$100.23M$138.60M$174.14M
Operating income$23.50M-$50.47M-$46.26M-$80.78M-$264.50M
Pretax income-$3.72M-$69.41M-$51.92M-$94.23M-$282.02M
Income tax$1.62M$0$0$0$0
Net income-$5.34M-$69.41M-$51.92M-$94.23M-$282.02M
EBITDA$24.77M-$49.01M-$44.67M-$79.12M-$262.57M
EPS (basic)-0.02-0.33-0.28-0.52-1.70
EPS (diluted)-0.02-0.33-0.28-0.52-1.70
Weighted avg. shares (diluted)257.16M210.95M187.47M182.78M165.95M
Balance sheet
Cash & equivalents$184.84M$53.55M$42.92M$93.17M$151.84M
Receivables$47.03M$34.37M$39.29M$40.28M$51.58M
Inventory$15.61M$16.24M$15.69M$21.57M$36.63M
Current assets$252.96M$113.83M$118.15M$185.18M$271.15M
PP&E, net$1.22M$2.20M$3.63M$5.21M$6.75M
Goodwill$59.04M$59.04M$59.04M$59.04M$59.04M
Intangibles—$0$36.04M$72.08M$108.13M
Total assets$376.56M$220.67M$241.70M$356.05M$529.35M
Current liabilities$162.94M$80.91M$99.87M$129.54M$261.05M
Short-term debt$0$0$17.50M$32.00M$97.54M
Long-term debt$48.25M$38.69M$17.18M$34.08M$0
Total debt$48.25M$38.69M$34.68M$66.08M$97.54M
Total liabilities$343.95M$269.86M$272.29M$350.82M$455.34M
Shareholders' equity$32.61M-$49.19M-$30.58M$5.23M$74.01M
Net debt-$136.59M-$14.86M-$8.24M-$27.09M-$54.30M
Shares outstanding265.42M224.85M194.58M184.14M177.00M
Cash flow statement
Operating cash flow$67.99M-$40.66M-$23.38M-$73.15M-$252.97M
Capital expenditure$291,000$33,000$0$114,000$59,000
Free cash flow$67.70M-$40.69M-$23.38M-$73.27M-$253.02M
Investing cash flow-$7.93M-$33,000$0-$114,000$39.94M
Financing cash flow$72.93M$49.66M-$25.21M$14.60M$133.73M
Depreciation & amortization$1.27M$1.46M$1.58M$1.65M$1.93M
Stock-based compensation$11.28M$7.78M$9.32M$17.85M$22.73M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.